Biocon has struck a deal with Bayer and Regeneron that will allow the global biosimilars player to launch its Yesafili biosimilar aflibercept rival to Eylea no later than 1 July 2025 in Canada.
Biocon Biologics has secured a date-certain launch for its Eylea (aflibercept) biosimilar, Yesafili, in Canada after striking a settlement deal with originators Bayer and Regeneron over the top-selling ophthalmic brand.
“Under the terms of the agreement, Biocon Biologics has secured a launch date for Yesafili 2mg for vials and prefilled syringes,” the firm disclosed,
Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.
Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.
Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
